Compare Repligen Corporation Common Stock (RGEN) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Union Pacific Corporation — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Union Pacific Corporation trades at $287 (market cap $167.74B). The key difference: Union Pacific Corporation is far larger — about 15.1× Repligen Corporation Common Stock's market cap, and Union Pacific Corporation pays a 2.01% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Union Pacific Corporation for 105 Days on average.
| RGEN | UNP | |
|---|---|---|
Market Cap | $11.14B | $167.74B |
Volume | 1,259,263 | 1,359,371 |
Sector | Health | Industrials |
52-Week High | $194.57 | $310.62 |
52-Week Low | $102.87 | $216.37 |
Typical Hold Time | 0 Days | 105 Days |
Enterprise Value | $11.02B | $196.80B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Union Pacific (UNP) trades at $286.43, up 1.73% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 28.85% net income margin and 39.7% ROE, supported by recent earnings beats in Q1 and Q2 2026. Positive sentiment is driven by analyst upgrades, a consensus buy rating, and a $332.10 price target, alongside developments in battery-electric locomotives and the pending Norfolk Southern combination.
The outlook for UNP is favorable, with earnings growth and dividend stability offering investment appeal. Risks include merger uncertainty, fuel cost pressures, and economic cyclicality, but the company's pricing power and infrastructure advantages provide a solid foundation for long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
